Crown Bioscience International Inc.

Amid WuXi AppTec ‘s withdrawal from the Biotechnology Innovation Organization (BIO) and the still emerging consequences of the proposed US BIOSECURE Act, multiple executives from Chinese biotechs and

China’s National Medical Products Administration (NMPA), the main drug regulator in the country, has rejected for the first time a biologics license application for a home-grown anti-PD-1/L1 antibody,

China has reacted strongly to US House Speaker Nancy Pelosi's visit to Taiwan, in a further ratcheting up of geopolitical tensions that could see the fall-out extending to the biopharma industry. Pelo

Zhongshan, Guangdong-based Akeso Pharmaceuticals obtained its first investigative new drug (IND) application approval from the US FDA on April 2 for its lead asset, AK104, a PD-1/CTLA-4 bispecific a